SCHEMBL15087403

SCHEMBL15087403

Pc1ccc(C(Cl)(c2ccccc2)c2ccccc2Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.48
TSHR P16473 4/20 0.41
KCNA3 P22001 2/20 0.38
CYP19A1 P11511 4/20 0.37
HTR2A P28223 2/20 0.37
HTR2C P28335 2/20 0.37
OPRK1 P41145 2/20 0.37
KCNH2 Q12809 2/20 0.37
CYP3A4 P08684 2/20 0.37
LMNA P02545 2/20 0.37
CYP1A2 P05177 2/20 0.37
ADRA1A P35348 1/20 0.37
MEN1 O00255 1/20 0.37
SLC22A1 O15245 1/20 0.37
NR1I2 O75469 1/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
TRPM2 O94759 1/20 0.37
ABCB11 O95342 1/20 0.37
EGFR P00533 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26214 0.88 KCNN4 (0.59) KCNN4TSHRKCNA3CYP19A1HTR2A
SCHEMBL3239466 0.88 KCNN4 (0.59) KCNN4TSHRKCNA3CYP19A1HTR2A
SCHEMBL29354141 0.88 KCNN4 (0.59) KCNN4TSHRKCNA3CYP19A1HTR2A
Chlorotriphenylmethane SCHEMBL27733223 0.86 KCNN4 (0.57) KCNN4TSHRKCNA3CYP19A1HTR2A
Hydrochloric Acid SCHEMBL29532967 0.86 KCNN4 (0.57) KCNN4TSHRKCNA3CYP19A1HTR2A
Hydrazine SCHEMBL26109949 0.84 KCNN4 (0.61) KCNN4TSHRKCNA3CYP19A1HTR2A
SCHEMBL11654993 0.84 KCNN4 (0.59) KCNN4TSHRKCNA3CYP19A1HTR2A
SCHEMBL15087409 0.82 TSHR (0.48) KCNN4TSHRCYP19A1CYP3A4CYP1A2
SCHEMBL23790036 0.81 KCNN4 (0.48) KCNN4TSHRKCNA3CYP19A1HTR2A
SCHEMBL13521990 0.81 KCNN4 (0.48) KCNN4TSHRKCNA3CYP19A1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183966-B2 Solid phase peptide synthesis via side chain attachment CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2019-01-22 US disclosed
US-20160362445-A1 SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2016-12-15 US disclosed
US-20160362445-A1 SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2016-12-15 US disclosed
US-9388212-B2 Solid phase peptide synthesis via side chain attachment CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2016-07-12 US disclosed
US-9388212-B2 Solid phase peptide synthesis via side chain attachment CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2016-07-12 US disclosed
US-20140235789-A1 SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2014-08-21 US disclosed
US-20140235789-A1 SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2014-08-21 US disclosed
WO-2013098802-A2 SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362445-A1 SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT HDGF, VIP, HDGFL3 KCNN4 4849/4885TSHR 1749/4885KCNA3 4765/4885
US-20140235789-A1 SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT HDGF, VIP, HDGFL3 KCNN4 4849/4885TSHR 1749/4885KCNA3 4765/4885
US-10183966-B2 Solid phase peptide synthesis via side chain attachment HDGF, VIP, HDGFL3 KCNN4 4849/4885TSHR 1749/4885KCNA3 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.